Positive data from multiple dose phase1 trial of CTP-354

A board to discuss future MS therapies in early stage (Phase I or II) trials.
Post Reply
User avatar
MSUK
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm
Contact:

Positive data from multiple dose phase1 trial of CTP-354

Post by MSUK »

Concert Pharmaceuticals Inc. announced Phase 1 data of CTP-354, a novel, potentially first-in-class, non-sedating, once-daily oral treatment for spasticity. In this multiple ascending dose trial, no sedation or ataxia was observed with CTP-354 and the drug was generally well tolerated across all dose cohorts.

Concert expects to initiate a Phase 2 clinical trial evaluating CTP-354 in patients with spasticity associated with spinal cord injury by the end of 2014..... Read More - http://www.ms-uk.org/emergingtherapies
MS-UK - http://www.ms-uk.org/
Post Reply
  • Similar Topics
    Replies
    Views
    Last post

Return to “Drug Pipeline”